Trump’s drug pricing push puts India’s pharma exports on notice

The move, analysts say, could mark a turning point in how Washington sources and prices medicines.

President Donald Trump. / Instagram/@realdonaldtrump

President Donald Trump’s sweeping drug pricing plan and AstraZeneca’s $50 billion pledge to expand U.S. manufacturing might have an adverse impact on India’s pharmaceutical industry, which supplies nearly 40 per cent of America’s generic drugs.

The plan, announced Oct. 10 at the White House, ties the cost of prescription medicines in the United States to the lowest available global rate — the so-called “Most Favoured Nation” pricing model. “Americans have paid the highest prices anywhere in the world for prescription drugs, by far,” Trump said.

ALSO READ: What does Trump's deal with Pfizer mean for drug prices?

This post is for paying subscribers only

SUBSCRIBE NOW

Comments

This is a Premium Article, available exclusively to our subscribers.

Read 500+ such News or articles every month by subscribing today!
Monthly

Free

Limited Access

Limited View

Free weekly E-Paper

Subscribe Now
Monthly

$10

Full Access

Unlimited View

Free weekly E-Paper

Free daily newsletter

Subscribe Now
Annual

$50

Full Access

Unlimited View

Free weekly E-Paper

Free daily newsletter

Subscribe Now
Start the conversation

Become a member of New India Abroad to start commenting.

Sign Up Now

Already have an account? Login